RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Sartorius Stedim Biotech - Stock

Sartorius Stedim Biotech Liabilities 2024

Sartorius Stedim Biotech Liabilities

5.1 B EUR

Ticker

DIM.PA

ISIN

FR0013154002

WKN

A2AJKS

In 2024, Sartorius Stedim Biotech's total liabilities amounted to 5.1 B EUR, a 95.02% difference from the 2.62 B EUR total liabilities in the previous year.

Sartorius Stedim Biotech Aktienanalyse

What does Sartorius Stedim Biotech do?

Sartorius Stedim Biotech SA is a company specializing in the development, manufacturing, and marketing of products and services for the biopharmaceutical industry. It was formed in 2007 through the merger of two companies, Sartorius and Stedim Biotech, and is headquartered in Aubagne, France. The company has a history dating back to 1870 when Florenz Sartorius, a mechanic, founded a precision scale factory in Göttingen, Germany. Over the years, Sartorius became a leading provider of laboratory scales and equipment worldwide. In 1951, the company was renamed Sartorius AG and expanded into filtration technology. Stedim Biotech, on the other hand, was founded in 1957 as a manufacturer of plastic products and is based in Aubagne, France. It has since become a leading provider of products and services for the biopharmaceutical industry. Today, Sartorius Stedim Biotech SA operates in four business segments: bioprocess systems, laboratory equipment, services, and specialized products. Its bioprocess systems segment includes products and solutions for biopharmaceutical production such as fermenters, bioreactors, cryogenic storage tanks, and filtration systems. The laboratory equipment segment offers a wide range of lab products including scales, pipettes, and analysis devices. The services segment includes consulting, training, and technical services for the biopharmaceutical industry. Lastly, the specialized products segment provides a broad range of products for specific applications, such as disposable syringes for medication administration. Sartorius Stedim Biotech SA has developed a wide range of products for the biopharmaceutical industry, including fermenters and bioreactors for the production of biological drugs, filtration systems for protein purification and cell culture media, disposable syringes for medication administration, and laboratory equipment for sample analysis. The company's business model is to offer a comprehensive range of products and services for the biopharmaceutical industry. It focuses on high-quality and innovative products and services, as well as providing consultation and support to its customers in solving challenges in biopharmaceutical production. Overall, Sartorius Stedim Biotech SA is a leading provider of products and services for the biopharmaceutical industry. Its broad product range and consultancy and support services make it an important partner for the biopharmaceutical industry in the production of biological drugs. Sartorius Stedim Biotech ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Sartorius Stedim Biotech's Liabilities

Sartorius Stedim Biotech's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Sartorius Stedim Biotech's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Sartorius Stedim Biotech's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Sartorius Stedim Biotech's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Sartorius Stedim Biotech’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Sartorius Stedim Biotech Stock

What is the level of liabilities of Sartorius Stedim Biotech this year?

Sartorius Stedim Biotech has a debt balance of 5.1 B EUR this year.

What were the liabilities of Sartorius Stedim Biotech compared to the previous year?

The liabilities of Sartorius Stedim Biotech have increased by 95.02% increased compared to the previous year.

What are the consequences of high debt for investors of Sartorius Stedim Biotech?

High liabilities can pose a risk for investors of Sartorius Stedim Biotech, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Sartorius Stedim Biotech?

Low liabilities mean that Sartorius Stedim Biotech has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Sartorius Stedim Biotech affect the company?

An increase in liabilities of Sartorius Stedim Biotech can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Sartorius Stedim Biotech affect the company?

A decrease in the liabilities of Sartorius Stedim Biotech can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Sartorius Stedim Biotech?

Some factors that can influence the liabilities of Sartorius Stedim Biotech include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Sartorius Stedim Biotech so important for investors?

The liabilities of Sartorius Stedim Biotech are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Sartorius Stedim Biotech take to modify the liabilities?

To change its liabilities, Sartorius Stedim Biotech can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Sartorius Stedim Biotech pay?

Over the past 12 months, Sartorius Stedim Biotech paid a dividend of 2.88 EUR . This corresponds to a dividend yield of about 1.81 %. For the coming 12 months, Sartorius Stedim Biotech is expected to pay a dividend of 3.69 EUR.

What is the dividend yield of Sartorius Stedim Biotech?

The current dividend yield of Sartorius Stedim Biotech is 1.81 %.

When does Sartorius Stedim Biotech pay dividends?

Sartorius Stedim Biotech pays a quarterly dividend. This is distributed in the months of April, April, April, May.

How secure is the dividend of Sartorius Stedim Biotech?

Sartorius Stedim Biotech paid dividends every year for the past 27 years.

What is the dividend of Sartorius Stedim Biotech?

For the upcoming 12 months, dividends amounting to 3.69 EUR are expected. This corresponds to a dividend yield of 2.32 %.

In which sector is Sartorius Stedim Biotech located?

Sartorius Stedim Biotech is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sartorius Stedim Biotech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sartorius Stedim Biotech from 4/4/2024 amounting to 0.69 EUR, you needed to have the stock in your portfolio before the ex-date on 4/2/2024.

When did Sartorius Stedim Biotech pay the last dividend?

The last dividend was paid out on 4/4/2024.

What was the dividend of Sartorius Stedim Biotech in the year 2023?

In the year 2023, Sartorius Stedim Biotech distributed 2.52 EUR as dividends.

In which currency does Sartorius Stedim Biotech pay out the dividend?

The dividends of Sartorius Stedim Biotech are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Sartorius Stedim Biotech stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Sartorius Stedim Biotech

Our stock analysis for Sartorius Stedim Biotech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sartorius Stedim Biotech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.